levodopa; L-3-hydroxytyrosine; L-3,4-dihydroxyphenylalanine; L-dopa (Dopar, Larodopa, Inbrija)

From Aaushi
Jump to navigation Jump to search

Introduction

Tradenames: Dopar, Larodopa.

Indications

Contraindications

Caution:

pregnancy category = c

safety in lactation = -

Dosage

Tabs: 100, 250 500 mg.

* inhalation powder (Inbrija)[5]

Pharmacokinetics

elimination via liver

1/2life = 1-3 hours

Adverse effects

Drug interactions

Laboratory

Mechanism of action

More general terms

More specific terms

Additional terms

Component of

References

  1. The Pharmacological Basis of Therapeutics, 9th ed. Gilman et al, eds. Permagon Press/McGraw Hill, 1996
  2. Drug Information & Medication Formulary, Veterans Affairs, Central California Health Care System, 1st ed., Ravnan et al eds, 1998 - not on National VA formulary
  3. Kaiser Permanente Northern California Regional Drug Formulary, 1998
  4. 4.0 4.1 4.2 Troiano AR et al. PET demonstrates reduced dopamine transporter expression in PD with dyskinesias. Neurology 2009 Apr 7; 72:1211. PMID: https://www.ncbi.nlm.nih.gov/pubmed/19020294
    Vingerhoets FJG. Dyskinesia in Parkinson disease: Back for the future? Neurology 2009 Apr 7; 72:1202. PMID: https://www.ncbi.nlm.nih.gov/pubmed/19349599
  5. 5.0 5.1 5.2 George J, FDA Approves Inhaled Levodopa for Parkinson's. Improved motor function when taken during 'off' episodes. MedPage Today. Dec. 26, 2018 https://www.medpagetoday.com/neurology/parkinsonsdisease/77104

Database